Stacy Fischer, Anthony “Tony” Bossis, Charles S Grob, Manish Agrawal, Shoshana Ungerleider
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Study investigates oral psilocybin for cluster headaches. Subjects receive placebo, low or high dose psilocybin in 3 sessions, with headache diary monitoring. Second round may involve low or high dose
Emmanuelle Schindler
Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.
Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna
KAP program offers innovative treatment for adolescents with emotional issues, focusing on family involvement. Successes and challenges of this unique approach are discussed.
Phil Wolfson
Neurological disorders like chronic pain and Alzheimer’s are being studied for psychedelic therapy benefits, expanding research beyond traditional mental health applications. Current studies explore potential applications for neurorehabilitation.
Julia Bornemann, James Close, Joel Castellanos, Robin Carhart-Harris
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.
Study investigates oral psilocybin effects on OCD symptoms and neural mechanisms mediating therapeutic effects. Clinical trial information available at NCT03356483.
Benjamin Kelmendi, Terence Ching
Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.
Jennifer Danby
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.